Within a particular cancer type, the three cancers in which KRAS mutations are the predominant RAS mutations are pancreatic cancer (~ 88%), colorectal adenocarcinoma (50%) [colon adenocarcinoma (50%) and rectal adenocarcinoma (50%)], and lung adenocarcinoma (32%). This evidence concerns the gene KRAS and lung adenocarcinoma.